‘Treating obesity for the next 100 years’: Ozempic-maker Novo Nordisk targets tripling of Apac patient base
By sales volumes for its GLP-1 drugs, the company’s largest markets in the region are Australia, Japan, South Korea and India With hundreds of millions living with obesity and diabetes…







